1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

13 Apr 2024
Admin
News Article

Modalis Announces Partnership with Ginkgo Bioworks

Overview

Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo’s global customers in the cell and gene therapy fields to access Modalis’ proprietary epigenome modulation technology, CRISPR-GNDM® (Guide Nucleotide-Directed Modulation). Modalis’ CRISPR-GNDM® Technology is capable of activating or suppressing any gene in a controlled manner without requiring DNA cleavage. This collaboration also creates a significant opportunity for Modalis to establish additional strategic partnerships.

About Ginkgo

Established in 2008 and headquartered in Boston, Massachusetts, Ginkgo is the pioneer in synthetic biology committed to driving innovation in cell and genome research and development.
Ginkgo offers the leading horizontal platform for cell programming and biosecurity, providing flexible, end-to-end services that solve challenges for organizations across diverse markets from food and agriculture to pharmaceuticals, industrial and specialty chemicals.
Ginkgo has recently expanded its offerings to include development and manufacturing services for gene and cell-therapy using AAV-based tissue specific drug delivery technology.
The Ginkgo Technology Network, a groundbreaking ecosystem of cutting-edge technology partners, is dedicated to driving innovation in its customer’s R&D programs.
The Technology Network brings together a diverse array of partners, spanning AI, genetic medicines, biologics, and manufacturing, with the aim of integrating their capabilities to provide customers with robust end-to-end solutions for successful R&D outcomes.

About Modalis

Modalis, founded in 2016, is headquartered in Tokyo, and conducts all research and development in Waltham, Massachusetts, USA.
Modalis is the pioneer and leader in CRISPR-based epigenome modulation technology, developing therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS, and cardiomyopathies.

Words from CEO: Modalis

Haru Morita, CEO of Modalis, stated: “We are pleased to be working with Ginkgo, a synthetic biology company that is building the leading horizontal platform for cell programming. We believe Ginkgo’s technology offerings and our proprietary epigenome modulation technology will be complementary in a wide range of fields, including the discovery and diagnosis of target disease genes and the development of novel cell and gene therapies.
In addition to making our proprietary technology available to a wide range of companies, this alliance will create additional opportunities for Modalis to establish strategic alliances directly with companies interested in developing novel treatments for serious diseases.

Words from Ginkgo

Anna Marie Wagner, Ginkgo’s SVP, Head of AI and Corporate Development, stated: “We believe that Modalis' proprietary epigenome modulation technology offers a competitive and attractive platform not only for the development of novel cell and gene therapeutics, but also in a wide range of markets including food, agriculture, diagnostics, and specialty chemicals.
We’re thrilled to have Modalis join Ginkgo’s Technology Network — their participation can bring significant value to our extensive base of biotech customers.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!